Fig. 4

Pyrotinib enhances the antitumor effect of T-DM1 in vitro. (a) The effects of various concentrations of pyrotinib and lapatinib on the viability of SK-BR-3 and JIMT-1 cells. Cell viability was assessed using a CCK-8 assay after 24 h. Y-axis: The Inhibition Ratio (%) represents the percentage of cell proliferation inhibition compared to untreated/control cells. (b) Cells were treated with T-DM1 (0.0001, 0.001, 0.01, 0.1, 1, 10 µg/mL) either alone or in combination with pyrotinib or lapatinib (SK-BR-3:0.01µM, JIMT-1:0.05µM). Cell viability was measured after 24 h of treatment. (c) Scratch assay to detect the effect of pyrotinib or lapatinib(SK-BR-3:0.01µM, JIMT-1:0.05µM) combined with T-DM1 (0.1 µg/mL) on the migration ability of breast cancer cells. Photograph the scratched area after 24 h. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = not significant. Results are representative of 3 independent replicates.